Research Update - Part 2 of 2

AstraZeneca PLC
08 June 2006

AstraZeneca Development Pipeline

8 June 2006



Line Extensions


       Compound                  Mechanism           Area under investigation   Phase        Estimated Filing
                                                                                             MAA           NDA
CV
Atacand                angiotensin II antagonist     diabetic retinopathy        III        > 2008         >2008
Atacand Plus           angiotensin II antagonist /   32/12.5 mg, 32/25 mg for    III          2008
                       thiazide diuretic             hypertension
Crestor                statin                        atherosclerosis             III        1H 2007       1H 2007
Crestor                statin                        outcomes CHF                III         >2008         >2008
Crestor                statin                        outcomes renal              III          2008          2008
Seloken/Toprol-XL      beta-blocker                  HCTZ combination            III       Launched        Filed

GI

Nexium                 proton pump inhibitor         NSAID GI side effects -     III      Promotable*      Filed
                                                     symptom resolution
Nexium                 proton pump inhibitor         NSAID GI side effects -     III       Launched        Filed
                                                     ulcer healing
Nexium                 proton pump inhibitor         peptic ulcer bleeding       III         >2008         >2008
Nexium Sachet          proton pump inhibitor         GERD                        III        Q4 2006        Filed
formulation
Nexium                 proton pump inhibitor         extra-oesophageal reflux    II          >2008         >2008
                                                     disease

Neuroscience

Seroquel SR            D2/5HT2 antagonist            schizophrenia               III        4Q 2006       3Q 2006
Seroquel               D2/5HT2 antagonist            bipolar maintenance         III        2H 2007       1H 2007
Seroquel               D2/5HT2 antagonist            bipolar depression          III        1H 2007        Filed
Seroquel SR            D2/5HT2 antagonist            generalised anxiety         III         2008         2H 2007
                                                     disorder
Seroquel SR            D2/5HT2 antagonist            major depressive            III         2008          2008
                                                     disorder
Onc/infection


Faslodex               oestrogen receptor antagonist 2nd line after aromatase    III        1 H2007      1 H 2007
                                                     inhibitor failure
Faslodex               oestrogen receptor antagonist 1st line advanced breast    III         >2008         >2008
                                                     cancer
Faslodex               oestrogen receptor antagonist adjuvant                    III         >2008         >2008
Iressa                 EGFR-TK inhibitor             head & neck cancer          III        2H 2007        1H 2007
Iressa                 EGFR-TK inhibitor             breast cancer               II          >2008         >2008

* Authorities stated these symptoms were already captured within the GERD label.
Text stating 'No clinical interaction with naproxen or rofecoxib' was approved.



       Compound                  Mechanism           Area under investigation   Phase        Estimated Filing
                                                                                            MAA           NDA
Respiratory

Symbicort Turbuhaler   inhaled steroid/fast onset,   Symbicort Maintenance       III         Filed
                       long-acting ss2 agonist       and Reliever Therapy for
                                                     asthma (SMART)
Symbicort pMDI         inhaled steroid/fast onset,   asthma                      III        Filed*        Filed
                       long-acting ss2 agonist

Symbicort pMDI         inhaled steroid/fast onset,   COPD                        III        Filed*        2008
                       long-acting ss2 agonist

* To be supplemented in 2008 with data supporting two additional strengths







NCE's



Phase III


Compound                         Mechanism           Area under investigation   Phase        Estimated Filing
                                                                                              MAA          NDA
CV

AGI-1067               Anti-atherogenic              atherosclerosis             III       1H 2007      1H 2007
AZD6140                ADP receptor antagonist       arterial thrombosis         III        >2008        >2008
Neuroscience
NXY-059                free radical trapping agent   stroke                      III       1H 2007      1H 2007


Oncology/Inf
Zactima                VEGF/EGF TKI inhibitor with   NSCLC                       III        >2008        >2008
                       RET kinase activity

AZD2171                 VEGF signalling inhibitor                               II/III      >2008        >2008
                       (VEGFR-TKI)                   NSCLC and CRC













NCE's



Phases I and II


       Compound                  Mechanism           Area under investigation   Phase        Estimated Filing
                                                                                             MAA          NDA
CV
AZD7009                antiarrhythmic IV             atrial fibrillation -        II         2008        2008
                                                     conversion
AZD9684                CPU inhibitor                 thrombosis                   II        >2008        >2008
AZD0837                thrombin inhibitor            thrombosis                   II        >2008        >2008
AZD2479                Reverse Cholesterol Transport dyslipidaemia                I         >2008        >2008
                       enhancer
AZD6610                PPAR alpha with 'partial      combined dyslipidaemia       I         >2008        >2008
                       gamma'
AZD8677                                              dyslipidaemia/               I         >2008        >2008
                                                     diabetes
GI
AZD9056                Ion channel blocker (P2X7)    inflammatory bowel           II        >2008        >2008
                                                     disease
AZD3355                inhibitor of transient lower  GERD                         I         >2008        >2008
                       oesophageal sphincter
                       relaxations  (TLESR)
AZD9272                Glutamate receptor modulator  GERD                          I        >2008        >2008
Neuroscience
AZD3480                Neuronal nicotinic receptor   cognitive disorders/         II        >2008        >2008
                       agonist                       alzheimers
AZD9272                Glutamate receptor modulator  neuropathic pain/anxiety     I         >2008        >2008
AZD2327                Enkephalinergic receptor      anxiety & depression         I         >2008        >2008
                       modulator
AZD5904                Enzyme inhibitor              multiple sclerosis           I         >2008        >2008
AZD1080                                              Alzheimers                   I         >2008        >2008
Onc/Infection

Zactima                VEGF/EGF TKI inhibitor with   medullary thyroid cancer     II        >2008        >2008
                       RET kinase activity

CytoFab                anti-TNF-alpha polyclonal     severe sepsis                II        >2008        >2008
                       antibody
ZD4054                 endothelin A receptor         prostate cancer              II        >2008        >2008
                       antagonist
AZD5896 (Patrin)       AGT inhibitor                 solid tumours                II        >2008        >2008
AZD0530                SRC kinase inhibitor          solid tumours and            I         >2008        >2008
                                                     haematological
                                                     malignancies
AZD6244                MEK  inhibitor                solid tumours                II        >2008        >2008
(ARRY-142886)
AZD1152                Aurora kinase inhibitor       solid tumours and            I         >2008        >2008
                                                     haematological
                                                     malignancies
AZD4769                                              solid tumours                I         >2008        >2008
AZD2281 (KU59436)      PARP inhibitor                breast cancer                I         >2008        >2008
AZD1689 (AQ4N)         Hypoxia activated cytotoxic   solid tumours                I         >2008        >2008


















Phases I and II (continued)


       Compound                  Mechanism                 Area under          Phase        Estimated Filing
                                                          investigation                      MAA          NDA
Respiratory
AZD9056                ion channel blocker (P2X7)    rheumatoid arthritis        II        >2008        >2008
AZD9056                ion channel blocker (P2X7)    COPD                        II        >2008        >2008
AZD8955                collagenase inhibitor         osteoarthritis              II        >2008        >2008
AZD8309                chemokine receptor antagonist rheumatoid arthritis        I         >2008        >2008
AZD8309                chemokine receptor antagonist COPD                        I         >2008        >2008
AZD3342                Protease inhibitor            COPD                        I         >2008        >2008
AZD1981                                              asthma                      I         >2008        >2008
AZD5672                                              rheumatoid arthritis        I         >2008        >2008
AZD5904                                              COPD                        I         >2008        >2008






NCE's



Pre Clinical


       Compound                  Mechanism            Area of investigation    Phase        Estimated Filing
                                                                                             MAA          NDA
CV

AZD8450                                              dyslipidaemia               PC        >2008        >2008
AZD6370                                              diabetes                    PC        >2008        >2008
AZD8593                                              haemostasis                 PC        >2008        >2008
AZD1175                                              diabetes/obesity            PC        >2008        >2008
AZD2207                                              diabetes/obesity            PC        >2008        >2008
AZD1305                                              arrhythmias                 PC        >2008        >2008
AZD4121                Cholesterol absorption        dyslipidaemia               PC        >2008        >2008
                       inhibitor
GI

AZD8081                                              functional GI disease       PC        >2008        >2008
AZD9335                                              GERD                        PC        >2008        >2008
Neuroscience

AZD3102                                              Alzheimers                  PC        >2008        >2008
AZD6538                                              neuropathic pain            PC        >2008        >2008
AZD8797                                              multiple sclerosis          PC        >2008        >2008
AZD3783                                              anxiety and depression      PC        >2008        >2008
AZD1940                                              nociceptive and             PC        >2008        >2008
                                                     neuropathic pain.
AZD9335                                              neuropathic pain            PC        >2008        >2008
AZD3241                                              Parkinson's disease         PC        >2008        >2008
AZD7512                                              depression & anxiety        PC        >2008        >2008
AZD3043 (TD-4756,      GABA-A receptor modulator     short acting                PC        >2008        >2008
Theravance)                                          anaesthetic


Pre Clinical (continued)


Compound                         Mechanism            Area of investigation    Phase        Estimated Filing
                                                                                             MAA          NDA
Onc/Infection

AZD9935                VEGF signalling inhibitor     solid tumours               PC        >2008        >2008
                       (VEGFR-TKI)
AZD0424                SRC kinase inhibitor          solid tumours               PC        >2008        >2008
AZD8931                                              solid tumours               PC        >2008        >2008
AZD4877                                              solid tumours               PC        >2008        >2008
AZD7762                                              solid tumours               PC        >2008        >2008
AZD5180                Anti-angiogenic               solid tumours               PC        >2008        >2008
AZD1845                                              solid tumours               PC        >2008        >2008
AZD8330                                              solid tumours               PC        >2008        >2008
AZD3646                                              solid tumours and           PC        >2008        >2008
                                                     haematological
                                                     malignancies
Respiratory

AZD6067                protease inhibitor            COPD                        PC        >2008        >2008
AZD6703                                              rheumatoid arthritis        PC        >2008        >2008
AZD6357                                              osteoarthritis              PC        >2008        >2008
AZD7928                                              COPD                        PC        >2008        >2008
AZD2392                                              asthma/rhinitis             PC        >2008        >2008
AZD1744                                              asthma/rhinitis             PC        >2008        >2008
AZD3825                                              asthma                      PC        >2008        >2008
AZD1236                                              COPD                        PC        >2008        >2008
AZD4818                                              COPD                        PC        >2008        >2008
AZD5069                                              COPD                        PC        >2008        >2008
AZD9668                                              COPD                        PC        >2008        >2008
AZD9215                                              asthma                      PC        >2008        >2008
AZD1678                                              asthma                      PC        >2008        >2008
AZD6605                                              osteoarthritis              PC        >2008        >2008






AstraZeneca Development Pipeline
Discontinued Projects vs Annual Results 2 February 2006



CVGI
    NCE/Line Extension                  Compound                 Area under investigation
LE                          Exanta                           prevention of stroke in AF
NCE                         AZD1092                          Diabetes
NCE                         Galida                           Diabetes/ Metabolic Syndrome

NCE                         AZD9343                          GERD
NCE                         AZD6538                          GERD



Respiratory and Inflammation
    NCE/Line Extension                  Compound                 Area under investigation
NCE                         AZD3778                          Indication rhinitis
NCE                         AZD2914                          COPD





Comments

As disclosure of compound information is balanced by the business need to
maintain confidentiality, information in relation to some compounds listed here
has not been disclosed at this time.



Compounds in development are displayed by phase.



Abbreviations:



PC - Pre-clinical: Candidate Drug accepted for development but not yet
administered to man.

MAA - Marketing Authorisation Application (Europe)

NDA - New Drug Application (USA)


                      This information is provided by RNS
            The company news service from the London Stock Exchange